Medicare Enrolled
Dr. Michael Norris, M.D.
Urology Physician · Long Beach, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Norris from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Norris?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Norris
Dr. Michael Norris is an urology physician in Long Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Norris performed 1,324 Medicare services across 623 unique beneficiaries.
Between the years covered by Open Payments, Dr. Norris received a total of $2,883 from 42 pharmaceutical and/or device companies across 121 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Norris is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 48% volume in CA
$2,883 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,324
Medicare services
Top 48% in CA for urology physician
623
Unique beneficiaries
$55
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~70 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
312 | $69 | $325 |
| Urinalysis, microscopic examination A laboratory test that examines a urine sample under a microscope to check for cells, crystals, bacteria, or other substances. |
231 | $3 | $20 |
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
221 | $34 | $40 |
| Limited retroperitoneal ultrasound A focused ultrasound exam of the area behind the abdominal cavity to evaluate specific structures. |
86 | $49 | $275 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
85 | $34 | $40 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
71 | $101 | $475 |
| Complicated insertion of bladder tube | 60 | $127 | $625 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
59 | $85 | $450 |
| Nucleic acid test for multiple organisms A laboratory test that uses amplified probe techniques to detect the genetic material of multiple organisms in a sample. |
54 | $69 | $75 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
21 | $216 | $900 |
| VRE nucleic acid detection test A laboratory test that uses amplified probe techniques to detect vancomycin-resistant Enterococcus (VRE) DNA in a patient sample. |
17 | $34 | $40 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
17 | $34 | $40 |
| MRSA nucleic acid detection test A laboratory test that uses amplified probe techniques to detect the genetic material of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. |
17 | $34 | $40 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
17 | $34 | $40 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
17 | $34 | $40 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
14 | $134 | $625 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
13 | $132 | $700 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $145 | $790 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$2,883
Total received (2018-2024)
Avg $412/year across 7 years
Top 47% in CA for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
121
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,607 (90.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$177 (6.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$100 (3.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$472
2023
$535
2022
$645
2021
$447
2020
$221
2019
$381
2018
$183
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$149
Myriad Genetic Laboratories, Inc.
$68
Sumitomo Pharma America, Inc.
$64
Endo USA, Inc.
$49
Teleflex LLC
$31
ACCORD HEALTHCARE, INC.
$23
Novo Nordisk Inc
$21
IMMUNITYBIO, INC.
$19
Boston Scientific Corporation
$17
Becton, Dickinson and Company
$17
Janssen Biotech, Inc.
$14
Top 3 companies account for 59.5% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$245
Sumitomo Pharma America, Inc.
$202
Astellas Pharma US Inc
$196
Myovant Sciences Inc.
$174
Laborie Medical Technologies Corp.
$174
Tolmar, Inc.
$161
Endo Pharmaceuticals Inc.
$157
Coloplast Corp
$128
COMSORT, Inc
$100
PFIZER INC.
$85
Janssen Biotech, Inc.
$84
Bayer HealthCare Pharmaceuticals Inc.
$82
Boston Scientific Corporation
$75
Teleflex LLC
$74
PROCEPT BioRobotics Corporation
$70
Myriad Genetic Laboratories, Inc.
$68
Dendreon Pharmaceuticals LLC
$66
AbbVie, Inc.
$63
Acerus Pharmaceuticals Corporation
$60
Blue Earth Diagnostics Limited
$59
Endo USA, Inc.
$49
UroGen Pharma, Inc.
$46
Olympus America Inc.
$44
Antares Pharma, Inc.
$41
NeoTract Inc.
$39
Progenics Pharmaceuticals, Inc.
$32
Cook Medical LLC
$28
Accord Healthcare, Inc.
$23
UROGEN PHARMA, INC.
$23
ACCORD HEALTHCARE, INC.
$23
Curium US LLC
$22
Merck Sharp & Dohme LLC
$21
Novo Nordisk Inc
$21
Alnylam Pharmaceuticals Inc.
$21
C. R. Bard, Inc. & Subsidiaries
$20
IMMUNITYBIO, INC.
$19
BOSTON SCIENTIFIC CORPORATION
$19
Becton, Dickinson and Company
$17
Ferring Pharmaceuticals Inc.
$14
Mission Pharmacal Company
$12
SRS Medical Systems, Inc.
$12
Allergan Inc.
$12
Top 3 companies account for 22.3% of all-time payments
Associated products mentioned in payments ›
ANKTIVA · AQUABEAM ROBOTIC SYSTEM · AVEED · Axumin · BOTOX · Bard Urinary Drainage Bag · CAMCEVI · Cook Medical Lasers · EDEX · ELIGARD · ERLEADA · GENERAL BPH · GENERAL THERAPIES · JELMYTO · KEYTRUDA · LUPRON DEPOT · Lupron · NOCDURNA · Natesto · Nubeqa · ORGOVYX · OXLUMO · Olympus Cysto-Resection · PROLARIS · PROVENGE · PYLARIFY · Porges Coloplast · REZUM · Rezum Generator · SPACEOAR VUE · SPEEDICATH · TOVIAZ · UROLIFT · Uribel · UroCuff · UroLift · UroLift System · VORTEK · XIAFLEX · XTANDI · XYOSTED · Xofigo
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Urology physicians within 10 mi
430
Per 100K population
4.4
County median income
$87,760
Nearest hospital
MEMORIALCARE LONG BEACH MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Norris is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Norris experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Norris performed 312 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Norris receive payments from pharmaceutical companies?
Yes. Dr. Norris received a total of $2,883 from 42 companies across 121 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Norris's costs compare to other urology physicians in Long Beach?
Dr. Norris's average Medicare payment per service is $55. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Norris) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Long Beach
Browse urology physicians in Long Beach ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in CA
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in CA
Which CA urology physicians receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Sumitomo Pharma America, Inc. Payments to Doctors
See all physicians who received payments from Sumitomo Pharma America, Inc.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology